Alteration of circulating miRNAs in SSc: MiR-30b regulates the expression of PDGF receptor β

Rheumatology (United Kingdom)

Volumn 52, Issue 11, 2013, Pages 1963-1972

  Tanaka, Shigeru ^a   Suto, Akira ^a   Ikeda, Kei ^a   Sanayama, Yoshie ^a   Nakagomi, Daiki ^a   Iwamoto, Taro ^a   Suzuki, Kotaro ^a   Kambe, Naotomo ^a   Matsue, Hiroyuki ^a   Matsumura, Ryutaro ^b   Kashiwakuma, Daisuke ^c   Iwamoto, Itsuo ^c   Nakajima, Hiroshi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b SAKURA NATIONAL HOSPITAL   (Japan)

^c ASAHI GENERAL HOSPITAL   (Japan)

Author keywords

miR 30b; miRNA; PDGF receptor ; SSc

Indexed keywords

BLEOMYCIN; CONNECTIVE TISSUE GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 4; LUCIFERASE; MICRORNA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PREDNISOLONE; TRANSFORMING GROWTH FACTOR BETA;

3' UNTRANSLATED REGION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FIBROBLAST; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCLERODERMA; SCORING SYSTEM; SKIN FIBROSIS;

MIR-30B; MIRNA; PDGF RECEPTOR Β; SSC;

ADULT; AGED; ANIMALS; BLEOMYCIN; CASE-CONTROL STUDIES; CELLS, CULTURED; DOWN-REGULATION; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICRORNAS; MIDDLE AGED; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SCLERODERMA, SYSTEMIC; SCLEROSIS; SKIN; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84886292833     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket254     Document Type: Article

References (39)

1. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005;26:587-95.
2. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117: 557-67.
3. Krieg T, Abraham D, Lafyatis R. Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast- epithelial cell interactions. Arthritis Res Ther 2007; 9(Suppl 2):S4.
4. Dragun D, Distler JH, Riemekasten G et al. Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology. Arthritis Rheum 2009;60: 907-11.
5. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004;15: 255-73.
6. Gay S, Jones RE, Huang GQ, et al. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 1989;92:301-3.
7. Klareskog L, Gustafsson R, Scheynius A, et al. Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 1990;33:1534-41.
8. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-76.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
10. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-8.
11. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007;9: 654-9.
12. Wittmann J, Jäck HM. microRNAs in rheumatoid arthritis: midget RNAs with a giant impact. Ann Rheum Dis 2011; 70(Suppl 1):i92-6.
13. Alevizos I, Illei GG. MicroRNAs as biomarkers in rheumatic diseases. Nat Rev Rheumatol 2010;6:391-8.
14. Maurer B, Stanczyk J, Jungel A, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 2010;62:1733-43.
15. Li H, Yang R, Fan X, et al. MicroRNA array analysis of microRNAs related to systemic scleroderma. Rheumatol Int 2012;32:307-13.
16. Honda N, Jinnin M, Kajihara I, et al. TGF-b-mediated downregulation of microRNA-196a contributes to the constitutive upregulated type I collagen expression in scleroderma dermal fibroblasts. J Immunol 2012;188: 3323-31.
17. Kawashita Y, Jinnin M, Makino T, et al. Circulating miR-29a levels in patients with scleroderma spectrum disorder. J Dermatol Sci 2010;61:67-9.
18. Makino K, Jinnin M, Kajihara I, et al. Circulating miR-142- 3p levels in patients with systemic sclerosis. Clin Exp Dermatol 2012;37:34-9.
19. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
20. LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
21. Murata K, Yoshitomi H, Tanida S, et al. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2010;12:R86.
22. Suto A, Nakajima H, Hirose K, et al. Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line C(epsilon) transcription of IL-4-stimulated B cells. Blood 2002;100:4565-73.
23. Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009;60:219-24.
24. Arnett FC. Is scleroderma an autoantibody mediated disease? Curr Opin Rheumatol 2006;18:579-81.
25. Pandit KV, Corcoran D, Yousef H, et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010;182:220-9.
26. Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res 2011;157:191-9.
27. Abraham DJ, Eckes B, Rajkumar V, et al. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep 2007;9: 136-43.
28. Leroy EC, Smith EA, Kahaleh MB, et al. A strategy for determining the pathogenesis of systemic sclerosis. Is transforming growth factor beta the answer?. Arthritis Rheum 1989;32:817-25.
29. Betel D, Koppal A, Agius P, et al. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol 2010;11:R90.
30. Distler JH, Jüngel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-22.
31. Duisters RF, Tijsen AJ, Schroen B, et al. miR-133 and miR- 30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009;104:170-8.
32. Nakerakanti SS, Bujor AM, Trojanowska M. CCN2 is required for the TGF-b induced activation of Smad1- Erk1/2 signaling network. PLoS One 2011;6:e21911.
33. Shi-Wen X, Chen Y, Denton CP, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004;15: 2707-19.
34. Soria A, Cario-AndréM, Lepreux S, et al. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. Dermatology 2008;216: 109-17.
35. Pope J, McBain D, Petrlich L, et al. Imatinib in active diffuse cutaneous systemic sclerosis: results of a sixmonth, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum 2011;63:3547-51.
36. Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, openlabel clinical trial. Ann Rheum Dis 2011;70:1003-9.
37. Khanna D, Saggar R, Mayes MD, et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum 2011;63: 3540-6.
38. Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009;5:200-6.
39. Denton CP, Merkel PA, Furst DE, et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323-33.